Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.
Researchers concluded that empagliflozin offers a promising dual benefit for glucose control and weight reduction, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback